194 related articles for article (PubMed ID: 29132830)
21. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.
Pierorazio PM; Johnson MH; Ball MW; Gorin MA; Trock BJ; Chang P; Wagner AA; McKiernan JM; Allaf ME
Eur Urol; 2015 Sep; 68(3):408-15. PubMed ID: 25698065
[TBL] [Abstract][Full Text] [Related]
22. The role of active surveillance of small renal masses.
Volpe A
Int J Surg; 2016 Dec; 36(Pt C):518-524. PubMed ID: 27321381
[TBL] [Abstract][Full Text] [Related]
23. Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort.
Finelli A; Cheung DC; Al-Matar A; Evans AJ; Morash CG; Pautler SE; Siemens DR; Tanguay S; Rendon RA; Gleave ME; Drachenberg DE; Chin JL; Fleshner NE; Haider MA; Kachura JR; Sykes J; Jewett MAS
Eur Urol; 2020 Sep; 78(3):460-467. PubMed ID: 32680677
[TBL] [Abstract][Full Text] [Related]
24. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
[TBL] [Abstract][Full Text] [Related]
25. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy.
Patel N; Cranston D; Akhtar MZ; George C; Jones A; Leiblich A; Protheroe A; Sullivan M
BJU Int; 2012 Nov; 110(9):1270-5. PubMed ID: 22564495
[TBL] [Abstract][Full Text] [Related]
26. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Boorjian S
Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
[TBL] [Abstract][Full Text] [Related]
27. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years.
Tracy CR; Raman JD; Donnally C; Trimmer CK; Cadeddu JA
Cancer; 2010 Jul; 116(13):3135-42. PubMed ID: 20564644
[TBL] [Abstract][Full Text] [Related]
28. Multicenter Evaluation of Multiparametric MRI Clear Cell Likelihood Scores in Solid Indeterminate Small Renal Masses.
Schieda N; Davenport MS; Silverman SG; Bagga B; Barkmeier D; Blank Z; Curci NE; Doshi AM; Downey RT; Edney E; Granader E; Gujrathi I; Hibbert RM; Hindman N; Walsh C; Ramsay T; Shinagare AB; Pedrosa I
Radiology; 2022 Jun; 303(3):590-599. PubMed ID: 35289659
[TBL] [Abstract][Full Text] [Related]
29. Active surveillance for small renal masses diagnosed in elderly or comorbid patients: looking for the best treatment strategy.
Brunocilla E; Borghesi M; Schiavina R; Palmieri F; Pernetti R; Monti C; Martorana G
Actas Urol Esp; 2014; 38(1):1-6. PubMed ID: 24126193
[TBL] [Abstract][Full Text] [Related]
30. Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management.
Silagy AW; Sanchez A; Manley BJ; Bensalah K; Bex A; Karam JA; Ljungberg B; Shuch B; Hakimi AA
Eur Urol Focus; 2019 Nov; 5(6):949-957. PubMed ID: 31040082
[TBL] [Abstract][Full Text] [Related]
31. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.
Cotta BH; Choueiri TK; Cieslik M; Ghatalia P; Mehra R; Morgan TM; Palapattu GS; Shuch B; Vaishampayan U; Van Allen E; Ari Hakimi A; Salami SS
Eur Urol; 2023 Aug; 84(2):166-175. PubMed ID: 37085424
[TBL] [Abstract][Full Text] [Related]
32. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma.
Kapur P; Christie A; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Xie XJ; Lotan Y; Margulis V; Brugarolas J
J Urol; 2014 Mar; 191(3):603-10. PubMed ID: 24076305
[TBL] [Abstract][Full Text] [Related]
33. The role of surveillance in the management of small renal masses.
Volpe A
ScientificWorldJournal; 2007 Apr; 7():860-8. PubMed ID: 17619771
[TBL] [Abstract][Full Text] [Related]
34. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.
Haddad AQ; Luo JH; Krabbe LM; Darwish O; Gayed B; Youssef R; Kapur P; Rakheja D; Lotan Y; Sagalowsky A; Margulis V
BJU Int; 2017 May; 119(5):741-747. PubMed ID: 28075543
[TBL] [Abstract][Full Text] [Related]
36. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
37. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
Mehdi A; Riazalhosseini Y
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
[TBL] [Abstract][Full Text] [Related]
38. Extended Duration of Active Surveillance of Small Renal Masses: A Prospective Cohort Study.
Whelan EA; Mason RJ; Himmelman JG; Matheson K; Rendon RA
J Urol; 2019 Jul; 202(1):57-61. PubMed ID: 30932757
[TBL] [Abstract][Full Text] [Related]
39. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma.
Chang A; Chakiryan NH; Du D; Stewart PA; Zhang Y; Tian Y; Soupir AC; Bowers K; Fang B; Morganti A; Teer JK; Kim Y; Spiess PE; Chahoud J; Noble JD; Putney RM; Berglund AE; Robinson TJ; Koomen JM; Wang L; Manley BJ
Eur Urol; 2022 Oct; 82(4):354-362. PubMed ID: 35718636
[TBL] [Abstract][Full Text] [Related]
40. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Carlo MI; Manley B; Patil S; Woo KM; Coskey DT; Redzematovic A; Arcila M; Ladanyi M; Lee W; Chen YB; Lee CH; Feldman DR; Hakimi AA; Motzer RJ; Hsieh JJ; Voss MH
Kidney Cancer; 2017 Jul; 1(1):49-56. PubMed ID: 30334004
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
